Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

作者：Sydney Lou Bonnick, Kenneth G. Saag, Douglas P. Kiel, Michael R. McClung, Marc C. Hochberg, Sherri‐Ann M. Burnett‐Bowie, Anthony Sebba, Risa Kagan, Erluo Chen, Desmond Thompson, Anne E. de Papp · 发表于：The Journal of Clinical Endocrinology & Metabolism · 年份：2006 · DOI：10.1210/jc.2005-2602 · 被引用次数：145 · 研究领域：Bone health and osteoporosis research、Bone health and treatments、Parathyroid Disorders and Treatments

OBJECTIVE: A 1-yr extension of the Fosamax Actonel Comparison Trial was completed to compare changes in bone mineral density (BMD), bone turnover, and upper gastrointestinal tolerability over 2 yr of treatment. DESIGN: This was a randomized, double-blind extension conducted at 72 U.S. sites. PATIENTS AND METHODS: Of the 1053 women who completed yr 1, 833 postmenopausal women with low BMD entered the extension, continuing their same treatment allocation [once-weekly (OW) alendronate 70 mg or OW risedronate 35 mg]. Changes in BMD at the hip trochanter, total hip, femoral neck, and lumbar spine and in markers of bone turnover were compared at 24 months. Tolerability was assessed by adverse experience reporting. RESULTS: Alendronate produced greater increases from baseline in BMD at 24 months than did risedronate at the trochanter (alendronate, 4.6%; risedronate, 2.5%, P < 0.001) as well as at all other BMD sites. Significantly more alendronate than risedronate patients had measured BMD increases of 0% or more and 3% or more at all BMD sites (P < 0.001), and fewer alendronate patients had measured decreases of 3% or more at all BMD sites. Significantly greater reductions in all biochemical markers of bone turnover occurred with alendronate, compared with risedronate. No differences were seen in occurrence or discontinuations due to upper gastrointestinal adverse experiences. CONCLUSIONS: Patients receiving 70 mg OW alendronate had greater gains in BMD, were more likely to maintai...